SCHEMBL1851864

SCHEMBL1851864

CC(C)(C)OC(=O)N1CCC(c2cc3ncc(C(=O)Nc4c(C(N)=O)oc5ccc(Br)cc45)cn3n2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.40
MAPT P10636 5/20 0.39
KMT2A Q03164 4/20 0.39
TP53 P04637 3/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 3/20 0.39
TSHR P16473 3/20 0.39
HSD17B10 Q99714 3/20 0.39
BACE1 P56817 1/20 0.38
GAA P10253 2/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
CRHBP P24387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4277820 0.89 KMT2A (0.40) GPR119MAPTKMT2ATP53ALDH1A1
SCHEMBL1851581 0.78 NPC1 (0.51) MAPTKMT2AALDH1A1HPGDKDM4E
SCHEMBL1848686 0.77 BACE1 (0.40) GPR119MAPTKMT2AALDH1A1HPGD
SCHEMBL1849293 0.76 BACE1 (0.50) GPR119MAPTKMT2AALDH1A1HPGD
SCHEMBL1852252 0.74 BACE1 (0.45) GPR119MAPTKMT2AALDH1A1HPGD
SCHEMBL1852123 0.74 HPGD (0.51) GPR119MAPTKMT2ATP53ALDH1A1
SCHEMBL1855351 0.73 CSNK2B (0.43) GPR119
SCHEMBL1852060 0.73 ESR2 (0.49) MAPTKMT2ATP53ALDH1A1HPGD
SCHEMBL1849864 0.73 EPHA2 (0.47) MAPTKMT2ATP53ALDH1A1HPGD
SCHEMBL1850058 0.72 ALDH1A1 (0.48) MAPTKMT2AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 GPR119 545/4885MAPT 1941/4885KMT2A 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.